Cargando…

Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era

Spinal muscular atrophy (SMA) is a lower motor neuron disease due to biallelic mutations in the SMN1 gene on chromosome 5. It is characterized by progressive muscle weakness of limbs, bulbar and respiratory muscles. The disease is usually classified in four different phenotypes (1–4) according to ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giorgia, Querin, Gomez Garcia de la Banda, Marta, Smeriglio, Piera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679720/ https://www.ncbi.nlm.nih.gov/pubmed/38020652 http://dx.doi.org/10.3389/fneur.2023.1226969

Ejemplares similares

Biomarkers of Spinal and Bulbar Muscle Atrophy (SBMA): A Comprehensive Review
por: Querin, Giorgia, et al.
Publicado: (2018)

Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy
por: Millere, Elina, et al.
Publicado: (2021)

Circulating microRNAs as potential biomarkers and therapeutic targets in spinal muscular atrophy
por: Chen, Tai-Heng
Publicado: (2020)

Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy
por: Kariyawasam, Didu S. T., et al.
Publicado: (2019)

Spinal Muscular Atrophy: The Treatment Approved
por: Tabet, Rabih, et al.
Publicado: (2017)

Addressing the implementation gap in advanced therapeutics for spinal muscular atrophy in the era of newborn screening programs
por: Leon-Astudillo, Carmen, et al.
Publicado: (2022)

Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment?
por: Savini, Giovanni, et al.
Publicado: (2021)

The Identification of Novel Biomarkers Is Required to Improve Adult SMA Patient Stratification, Diagnosis and Treatment
por: Smeriglio, Piera, et al.
Publicado: (2020)

The value of serum creatinine as biomarker of disease progression in spinal and bulbar muscular atrophy (SBMA)
por: Blasi, Lorenzo, et al.
Publicado: (2023)

Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy
por: Lombardi, Vittoria, et al.
Publicado: (2019)

Editorial: Spinal Muscular Atrophy: Evolutions and Revolutions of Modern Therapy
por: Finkel, Richard S., et al.
Publicado: (2020)

Expression of Human Endogenous Retrovirus-K in Spinal and Bulbar Muscular Atrophy
por: Rex, Cody, et al.
Publicado: (2019)

Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy
por: Elsheikh, Bakri, et al.
Publicado: (2021)

Correlation Between Maximal Tongue Pressure and Swallowing Function in Spinal and Bulbar Muscular Atrophy
por: Gwak, Dae-Won, et al.
Publicado: (2021)

Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy
por: Kotulska, Katarzyna, et al.
Publicado: (2021)

Serum Creatine, Not Neurofilament Light, Is Elevated in CHCHD10-Linked Spinal Muscular Atrophy
por: Järvilehto, Julius, et al.
Publicado: (2022)

Real-World Data on Access to Standards of Care for People With Spinal Muscular Atrophy in the UK
por: Muni-Lofra, Robert, et al.
Publicado: (2022)

Sociodemographic and clinical characteristics and access to health care in patients with spinal muscular atrophy in Argentina
por: Vazquez, Gabriel Adolfo, et al.
Publicado: (2023)

Prevalence of metabolic syndrome and non-alcoholic fatty liver disease in a cohort of italian patients with spinal-bulbar muscular atrophy
por: FRANCINI-PESENTI, FRANCESCO, et al.
Publicado: (2018)

Update on Biomarkers in Spinal Muscular Atrophy
por: Pino, Megan G, et al.
Publicado: (2021)

Innovating spinal muscular atrophy models in the therapeutic era
por: Signoria, Ilaria, et al.
Publicado: (2023)

Spinal Cord Imaging in Amyotrophic Lateral Sclerosis: Historical Concepts—Novel Techniques
por: El Mendili, Mohamed Mounir, et al.
Publicado: (2019)

The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs
por: Hensel, Niko, et al.
Publicado: (2020)

Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen
por: Wurster, Claudia D., et al.
Publicado: (2019)

Spinal Muscular Atrophy and Communicating Hydrocephalus: A Novel or a Well-Established Rare Association?
por: Alkhars, Fatimah Z, et al.
Publicado: (2020)

Lowered oxidative capacity in spinal muscular atrophy, Jokela type; comparison with mitochondrial muscle disease
por: Ratia, Nadja, et al.
Publicado: (2023)

A New Method for Measuring Bell-Shaped Chest Induced by Impaired Ribcage Muscles in Spinal Muscular Atrophy Children
por: LoMauro, Antonella, et al.
Publicado: (2018)

Ethical Perspectives on Treatment Options with Spinal Muscular Atrophy Patients
por: Yeo, Crystal J. J., et al.
Publicado: (2022)

Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives
por: Farrar, Michelle A, et al.
Publicado: (2018)

Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis
por: Darbà, Josep, et al.
Publicado: (2019)

Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment
por: Nigro, Elisa, et al.
Publicado: (2023)

Healthcare Utilization, Costs of Care, and Mortality Among Patients With Spinal Muscular Atrophy
por: Tan, Hiangkiat, et al.
Publicado: (2019)

Healthcare Utilization, Costs of Care, and Mortality Among Patients With Spinal Muscular Atrophy
por: Tan, Hiangkiat, et al.
Publicado: (2019)

Identifying Biomarkers of Spinal Muscular Atrophy for Further Development
por: Glascock, Jacqueline, et al.
Publicado: (2023)

Scoliosis in Spinal Muscular Atrophy Type 1 in the Nusinersen Era
por: Al Amrani, Fatima, et al.
Publicado: (2022)

Longitudinal characterization of biomarkers for spinal muscular atrophy
por: Bonati, Ulrike, et al.
Publicado: (2017)

AAV9-Mediated Expression of SMN Restricted to Neurons Does Not Rescue the Spinal Muscular Atrophy Phenotype in Mice
por: Besse, Aurore, et al.
Publicado: (2020)

Exploratory evaluation of an eye-tracking system in patients with advanced spinal muscular atrophy type I receiving nusinersen
por: Yae, Yukako, et al.
Publicado: (2022)

Cognitive impairment in Chinese adult patients with type III spinal muscular atrophy without disease-modifying treatment
por: Hu, Ying, et al.
Publicado: (2023)

Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy
por: Cordts, Isabell, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h3i6425n6i4hhio22c67vjsnk1